FrancophonIA/ELRC3.0 huggingface dataset:
English: Time to MCyR for responders onlyb, weeks (95% CI) Duration of MCyR
Croatian: Vrijeme do MCyR-a samo za bolesnike koji su odgovorili na liječenje b, u tjednima (95% CI) Trajanje MCyR-a b
English: The dose at which no adverse reproductive effects were observed in males (30 mg/kg/day) and females (3 mg/kg/day) resulted in exposures equal to 0.6-times and 0.3-times, respectively, the human exposure resulting from the clinical dose of 400 mg, and 0.5-times and 0.2-times, respectively, the human exposure resulting from the clinical dose of 500 mg (based on unbound AUC in the respective species).
Croatian: Doza pri kojoj nije bilo opaženih štetnih učinaka na reprodukciju u mužjaka (30 mg/kg/dan) i ženki (3 mg/kg/dan) rezultirala je izloženosti lijeku jednakoj 0,6 puta, odnosno 0,3 puta izloženosti u ljudi nakon kliničke doze od 400 mg i 0,5 puta odnosno 0,2 puta izloženosti u ljudi nakon kliničke doze od 500 mg (na temelju AUC-a nevezanog spoja u odgovarajućim vrstama).
English: No evidence of leukaemia (NEL): Meets all other criteria for CHR except may have thrombocytopenia (platelets greater than or equal to 20,000/mm and less than 100,000/mm 3) and/or neutropenia (ANC greater than or equal to 0.5×10
Croatian: Bez dokaza leukemije: zadovoljava sve ostale kriterije za CHR osim što može imati trombocitopeniju (broj trombocita veći ili jednak 20 000/mm
English: Bosulif 400 mg film-coated tablets EU/1/13/818/006
Croatian: Bosulif 400 mg filmom obložene tablete EU/1/13/818/006
English: Among these patients, the median time to first event was 28 days (range: 1 to 2,633 days) and the median duration per event was 15 days (range: 1 to 1,529 days).
Croatian: Među tim bolesnicima, medijan vremena do prvog događaja bio je 28 dana (raspon: 1 do 2633 dana), a medijan trajanja po događaju bio je 15 dana (raspon: 1 do 1529 dana).
English: - acute inflammation of the pancreas (acute pancreatitis).
Croatian: Manje često Pankreatitis (uključujući akutni pankreatitis)
English: The descriptions included below are based on the safety population of 1,272 patients who received at least 1 dose of bosutinib for either newly-diagnosed CP CML or were resistant or intolerant to prior therapy with CP, AP, or BP CML, or Ph+ ALL.
Croatian: Opisi koji se nalaze u nastavku temelje se na populaciji uključenoj u ispitivanju sigurnosti lijeka koja se sastojala od 1272 bolesnika koji su dobili najmanje jednu dozu bosutiniba za novodijagnosticirani KML u kroničnoj fazi ili koji su bili rezistentni ili nisu podnosili prethodnu terapiju u kroničnoj, aktivnoj ili blastičnoj fazi kronične mijeloične leukemije, ili za Ph+ ALL.
English: Abbreviations: BCR-ABL=breakpoint cluster region-Abelson; CP=chronic phase; CML=chronic myelogenous leukaemia; MCyR=major cytogenetic response; N/n=number of patients; Resp=responders; Eval=evaluable.
Croatian: Kratice: BCR ABL = engl. breakpoint cluster region-Abelson; CP = kronična faza; KML = kronična mijeloična leukemija; MCyR= veliki citogenetski odgovor, N/n = broj bolesnika; Resp = bolesnici koji su odgovorili na liječenje (engl. responders), Eval = procjenjivo (engl. evaluable).
English: C] radiolabelled bosutinib to lactating
Croatian: C] obilježenog bosutiniba u
English: Bosulif 500 mg film-coated tablets EU/1/13/818/003
Croatian: Bosulif 500 mg filmom obložene tablete EU/1/13/818/003
English: In a study of 27 healthy subjects, in whom a single dose of 500 mg bosutinib was co-administered with a single dose of 150 mg dabigatran etexilate mesylate (a P-glycoprotein [P-gp] substrate) under fed conditions, bosutinib did not increase Cmax or AUC of dabigatran in plasma, as compared with administration of dabigatran etexilate mesylate alone.
Croatian: U ispitivanju provedenom u 27 zdravih ispitanika, u kojih je jedna doza od 500 mg bosutiniba primijenjena istodobno s jednom dozom od 150 mg dabigatraneteksilatmesilata (supstrata pglikoproteina [P-gp]) u stanju sitosti, bosutinib nije povećao Cmax niti AUC dabigatrana u plazmi, u usporedbi s primjenom samog dabigatraneteksilatmesilata.
English: - joint pain, back pain.
Croatian: Artralgija, bol u leđima
English: Note: MMR was defined as ≤ 0.1% BCR-ABL/ABL ratio by international scale (corresponding to ≥ 3 log reduction from standardised baseline) with a minimum of 3,000 ABL transcripts assessed by the central laboratory.
Croatian: Napomena: MMR je definiran kao omjer BCR-ABL/ABL ≤ 0,1% prema međunarodnoj ljestvici (što odgovara smanjenju za ≥ 3 log od standardizirane početne vrijednosti) s minimumom od 3000 ABL transkripata, kako je procijenio središnji laboratorij.
English: In addition, fluid retention can also be managed by withholding bosutinib temporarily, dose reduction, and/or discontinuation of bosutinib (see sections 4.2 and 4.8).
Croatian: Nadalje, zadržavanje tekućine se može također zbrinjavati privremenim prekidom liječenja bosutinibom, smanjivanjem doze i/ili trajnim prekidom liječenja bosutinibom (vidjeti dijelove 4.2 i 4.8).
English: Bosulif 100 mg film-coated tablets EU/1/13/818/001
Croatian: Bosulif 100 mg filmom obložene tablete EU/1/13/818/001
English: Abbreviations: BCR-ABL=breakpoint cluster region-Abelson; CI=confidence interval; CMH=Cochran-Mantel-Haenszel; CCyR=complete cytogenetic response; mITT=modified intent-to-treat; MMR=major molecular response; N/n=number of patients; Ph+=Philadelphia chromosome-positive.
Croatian: Kratice: BCR-ABL = engl. breakpoint cluster region-Abelson; CI = interval pouzdanosti; CMH = Cochran-Mantel-Haenszel; CcyR = potpun citogenetski odgovor; mITT = modificirana populacija planirana za liječenje; MMR = značajan molekularni odgovor; N/n = broj bolesnika; Ph+ = pozitivan Philadelphia kromosom.
English: Red oval (width: 9.5 mm; length: 18.3 mm) biconvex, film-coated tablet debossed with “Pfizer” on one side and “500”on the other side.
Croatian: Crvena, ovalna (širina: 9,5 mm; duljina: 18,3 mm), bikonveksna, filmom obložena tableta s utisnutom oznakom "Pfizer" na jednoj strani i "500" na drugoj strani.
English: Myelosuppression should/can be managed by withholding bosutinib temporarily, dose reduction, and/or discontinuation of bosutinib (see sections 4.2 and 4.8).
Croatian: Mijelosupresija se mora/smije zbrinjavati privremenim prekidom bosutiniba, smanjivanjem doze i/ili trajnim prekidom liječenja bosutinibom (vidjeti dijelove 4.2 i 4.8).
English: In a study of 24 healthy subjects in whom 5 daily doses of 400 mg ketoconazole (a strong CYP3A inhibitor) were co-administered with a single dose of 100 mg bosutinib under fasting conditions, ketoconazole increased bosutinib Cmax by 5.2-fold, and bosutinib AUC in plasma by 8.6-fold, as compared with administration of bosutinib alone.
Croatian: U ispitivanju provedenom u 24 zdrava ispitanika koji su natašte uzimali 5 dnevnih doza od 400 mg ketokonazola (snažan inhibitor CYP3A) istodobno s jednom dozom od 100 mg bosutiniba, ketokonazol je povisio Cmax bosutiniba za 5,2 puta i AUC bosutiniba u plazmi za 8,6 puta, u usporedbi s primjenom samog bosutiniba.
English: MMR was defined as ≤ 0.1% BCR-ABL/ABL ratio by international scale (corresponding to ≥ 3 log reduction from standardised baseline) with a minimum of 3,000 ABL transcripts as assessed by the central laboratory.
Croatian: MMR je definiran kao omjer BCR-ABL/ABL ≤ 0,1% prema međunarodnoj ljestvici (što odgovara smanjenju za ≥ 3 log od standardizirane početne vrijednosti) s minimumom od 3000 ABL transkripata, kako je procijenio središnji laboratorij.
English: The exposure at the highest dose tested in rabbits (10 mg/kg/day) that did not result in adverse foetal effects was 0.9-times and 0.7-times the human exposure resulting from the clinical dose of 400 mg or 500 mg, respectively (based on unbound AUC in the respective species).
Croatian: Izloženost najvišoj dozi ispitanoj u kunića (10 mg/kg/dan) koja nije rezultirala štetnim učincima na fetusu bila je 0,9 puta odnosno 0,7 puta izloženosti u ljudi nakon kliničke doze od 400 mg, odnosno 500 mg (na temelju AUC-a nevezanog spoja u odgovarajućim vrstama).
English: Caution is warranted if mild CYP3A inducers are used concomitantly with bosutinib.
Croatian: Potreban je oprez ako se s bosutinibom istodobno primjenjuju blagi induktori CYP3A.
English: The dose at which no adverse development effects were observed (10 mg/kg/day) resulted in exposures equal to 1.3-times and 1.0-times human exposure resulting from the clinical dose of 400 mg and 500 mg, respectively (based on unbound AUC in the respective species).
Croatian: Doza pri kojoj nije bilo opaženih štetnih učinaka na razvoj (10 mg/kg/dan) rezultirala je izloženosti lijeku jednakoj 1,3 puta, odnosno 1,0 puta izloženosti u ljudi nakon kliničke doze od 400 mg, odnosno 500 mg (na temelju AUC-a nevezanog spoja u odgovarajućim vrstama).
English: When a single oral dose of bosutinib (400 mg) was co-administered with multiple-oral doses of lansoprazole (60 mg) in a study of 24 healthy fasting subjects, bosutinib Cmax and AUC decreased to 54% and 74%, respectively, of the values seen when bosutinib (400 mg) was given alone.
Croatian: U ispitivanju u 24 zdrava ispitanika kod istodobne primjene natašte jedne peroralne doze bosutiniba (400 mg) s višekratnim peroralnim dozama lanzoprazola (60 mg), Cmax i AUC bosutiniba smanjili su se na 54% odnosno 74% vrijednosti, u odnosu na primjenu bosutiniba (400 mg) samog.
English: Bosutinib 400 mg study
Croatian: Ispitivanje bosutiniba u dozi od 400 mg
English: Bosulif 500 mg film-coated tablets are red, oval biconvex, debossed with “Pfizer” on one side and “500” on the other side.
Croatian: Bosulif 500 mg filmom obložene tablete su crvene, ovalne, bikonveksne, s utisnutom oznakom "Pfizer" na jednoj strani i "500" na drugoj strani.
English: Bosulif 400 mg film-coated tablets are orange, oval biconvex, debossed with “Pfizer” on one side and “400” on the other side.
Croatian: Bosulif 400 mg filmom obložene tablete su narančaste, ovalne, bikonveksne, s utisnutom oznakom "Pfizer" na jednoj strani i "400" na drugoj strani.
English: In a study of 20 healthy subjects, in whom a single dose of 125 mg aprepitant (a moderate CYP3A inhibitor) was co-administered with a single dose of 500 mg bosutinib under fed conditions, aprepitant increased bosutinib Cmax by 1.5-fold, and bosutinib AUC in plasma by 2.0-fold, as compared with administration of bosutinib alone.
Croatian: U ispitivanju s 20 zdravih ispitanika, u kojih je jedna doza od 125 mg aprepitanta (umjerenog inhibitora CYP3A) primijenjena istodobno s jednom dozom od 500 mg bosutiniba u stanju sitosti, aprepitant je povećao Cmax bosutiniba za 1,5 puta i AUC bosutiniba u plazmi za 2,0 puta u usporedbi s primjenom samog bosutiniba.
English: The t½ of bosutinib increased in hepatic impaired patients as compared to the healthy subjects.
Croatian: U bolesnika s oštećenjem jetre t1/2 bosutiniba porastao je u odnosu na zdrave ispitanike.
English: Bosulif 100 mg film-coated tablets Bosulif 400 mg film-coated tablets Bosulif 500 mg film-coated tablets
Croatian: Bosulif 100 mg filmom obložene tablete Bosulif 400 mg filmom obložene tablete Bosulif 500 mg filmom obložene tablete
English: Platelets < 50 × 109/L
Croatian: ABN a < 1,0×10 9/l i/ili trombociti < 50×10 9/l
English: Blood and lymphatic system disorders Very common Thrombocytopenia (including Platelet count decreased), Neutropenia (including Neutrophil count decreased), Anaemia (including haemoglobin decreased)
Croatian: Trombocitopenija (uključujući smanjenje broja trombocita), neutropenija (uključujući smanjenje broja neutrofila), anemija (uključujući snižene vrijednosti hemoglobina)
English: Treatment-naïve CML patients treated with 500 mg showed a median eGFR decline of 5.1 ml/min/1.73 m2 at 3 months, of 9.2 ml/min/1.73 m2 at 12 months and of up to 16.3 ml/min/1.73 m2 until 5 years follow-up for patients on treatment.
Croatian: Prethodno neliječeni bolesnici s KML-om liječeni dozom od 500 mg pokazali su medijan smanjenja vrijednosti eGFR-a od 5,1 ml/min/1,73 m 2 nakon 3 mjeseca, od 9,2 ml/min/1,73 m 2 nakon 12 mjeseci i do
English: Pericardial effusion, Electrocardiogram QTc prolonged (including Long
Croatian: Perikardijalni izljev, produljenje QTc intervala u elektrokardiogramu
English: A decline over time in estimated glomerular filtration rate (eGFR) has been observed in patients treated with bosutinib in clinical studies.
Croatian: U bolesnika liječenih bosutinibom u kliničkim ispitivanjima zabilježeno je smanjenje procijenjene brzine glomerularne filtracije (eGFR) tijekom vremena.
English: These analyses allow baseline responders who maintained response post-baseline to be responders.
Croatian: Te analize omogućuju bolesnicima koji su odgovorili na liječenje na početku i održali odgovor nakon početka da zadrže status bolesnika koji su odgovorili na liječenje.
English: Uncommon Anaphylactic shock, Hypersensitivity Metabolism and nutrition disorders Very common Decreased appetite Common
Croatian: Poremećaji imunološkog sustava Manje često Anafilaktički šok, preosjetljivost Poremećaji metabolizma i prehrane Vrlo često
English: Bosulif 100 mg film-coated tablets Bosulif 400 mg film-coated tablets Bosulif 500 mg film-coated tablets bosutinib
Croatian: Bosulif 100 mg filmom obložene tablete Bosulif 400 mg filmom obložene tablete Bosulif 500 mg filmom obložene tablete bosutinib
English: 28 Film-coated tablets.
Croatian: 28 filmom obloženih tableta. 30 filmom obloženih tableta.
English: Bosulif 500 mg is available in blisters containing either 14 or 15 film-coated tablets in cartons of 28 or 30 film-coated tablets.
Croatian: Bosulif 500 mg je dostupan u blisterima koji sadrže 14 ili 15 filmom obloženih tableta u kutiji s 28 ili 30 filmom obloženih tableta.
English: Pleural effusion Uncommon Pulmonary hypertension, Respiratory failure, Acute pulmonary oedema Gastrointestinal disorders Very common Diarrhoea, Vomiting, Nausea, Abdominal pain (including Abdominal discomfort, Abdominal pain lower, Abdominal pain upper, Abdominal tenderness, Gastrointestinal pain)
Croatian: Proljev, povraćanje, mučnina, bol u abdomenu (uključujući nelagodu u abdomenu, bol u donjem dijelu abdomena, bol u gornjem dijelu abdomena, osjetljivost abdomena, bol u gastrointestinalnom sustavu)
English: Hepatobiliary disorders
Croatian: Hematološke nuspojave
English: EU/1/13/818/003 28 film-coated tablets EU/1/13/818/004 30 film-coated tablets
Croatian: EU/1/13/818/003 (28 filmom obloženih tableta) EU/1/13/818/004 (30 filmom obloženih tableta)
English: - respiratory failure.
Croatian: Poremećaji jetre.
English: Bosulif 400 mg is available in blisters containing either 14 or 15 film-coated tablets in cartons of 28 or 30 film-coated tablets.
Croatian: Bosulif 400 mg je dostupan u blisterima koji sadrže 14 ili 15 filmom obloženih tableta u kutiji s 28 ili 30 filmom obloženih tableta.
English: Bosulif 100 mg is available in blisters containing either 14 or 15 film-coated tablets in cartons of 28 or 30 film-coated tablets or 112 film-coated tablets.
Croatian: Bosulif 100 mg je dostupan u blisterima koji sadrže 14 ili 15 filmom obloženih tableta u kutiji s 28 ili 30 ili 112 filmom obloženih tableta.
English: Month 3 (95% CI)
Croatian: 3. mjesec (95% CI)
English: Acute kidney injury, Renal failure, Renal impairment General disorders and administration site conditions Very common Pyrexia, Asthenia, Oedema (including Face oedema, Localised oedema, Oedema peripheral), Fatigue (including Malaise)
Croatian: Pireksija, astenija, edem (uključujući edem lica, lokalizirani edem, periferni edem), umor (uključujući malaksalost)
English: Microcrystalline cellulose (E460) Croscarmellose sodium (E468) Poloxamer 188
Croatian: Jezgra tablete mikrokristalična celuloza (E460) umrežena karmelozanatrij (E468) poloksamer 188 povidon (E1201) magnezijev stearat (E470b)
English: Month 9 (95% CI)
Croatian: 9. mjesec (95% CI)
English: Time to OHR for responders only, weeks (95% CI)
Croatian: Vrijeme do OHR-a samo za bolesnike koji su odgovorili na liječenje, u tjednima (95% CI)
English: For patients previously treated with both imatinib and at least 1 additional TKI, the endpoints include the cumulative MCyR rate, time to and duration of MCyR, and time to and duration of CHR. For patients with AP and BP CML previously treated with at least 1 prior TKI (imatinib), the endpoints were cumulative overall haematological response (OHR) and time to and duration of OHR.
Croatian: U bolesnika s AP i BP KML-om (engl. accelerated phase, AP, i blast phase, BP) koji su prethodno liječeni najmanje 1 TKI-om (imatinib), mjere ishoda bile su kumulativni ukupni hematološki odgovor (engl. overall hematologic response, OHR), vrijeme do OHR-a i njegovo trajanje.
English: If you get any side effects, talk to your doctor or pharmacist or nurse.
Croatian: Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
English: The analyses allow baseline responders who maintained response post-baseline to be responders.
Croatian: Analize omogućuju bolesnicima koji su odgovorili na liječenje na početku i održali odgovor nakon početka da zadrže status bolesnika koji su odgovorili na liječenje.
English: Month 6 (95% CI)
Croatian: 6. mjesec (95% CI)
English: - boceprevir and telaprevir, used to treat hepatitis C. - aprepitant, used to prevent and control nausea (feeling sick) and vomiting.
Croatian: fosamprenavir i darunavir, koriste se za liječenje virusa humane imunodeficijencije (HIV)/SIDA; - boceprevir i telaprevir, koriste se za liječenje hepatitisa C; - aprepitant, koristi se za sprječavanje i kontrolu mučnine i povraćanja; - imatinib, koristi se za liječenje jedne vrste leukemije; - krizotinib, koristi se za liječenje jedne vrste raka pluća koja se zove rak pluća nemalih stanica.
English: Pretreated and advanced stage CML patients on 500 mg showed a median eGFR decline of 5.3 ml/min/1.73 m2 at 3 months, of 7.6 ml/min/1.73 m2 at 12 months and of up to 10.9 ml/min/1.73 m2 in up to 4 years on treatment.
Croatian: Bolesnici s prethodno liječenim i uznapredovalim KML-om liječeni dozom od 500 mg imali su medijan smanjenja vrijednosti eGFR-a od 5,3 ml/min/1,73 m nakon 3 mjeseca, od 7,6 ml/min/1,73 m 2 nakon 12 mjeseci i do
English: In patients with newly-diagnosed CP CML treated with 400 mg, the median decline from baseline in eGFR was 4.9 ml/min/1.73 m2 at 3 months, 9.2 ml/min/1.73 m2 at 6 months and 11.1 ml/min/1.73 m2 at 12 months.
Croatian: U bolesnika s novodijagnosticiranim KML-om u u kroničnoj fazi liječenih dozom od 400 mg, medijan smanjenja u odnosu na početne vrijednosti eGFR-a iznosio je 4,9 ml/min/1,73 m2 nakon 3 mjeseca,
English: - diarrhoea, vomiting, stomach pain, nausea.
Croatian: Akutno oštećenje bubrega, zatajenje bubrega, oštećenje bubrega
English: Bosutinib exhibits dose proportional increases in AUC and Cmax, over the dose range of 200 to 600 mg. Food increased bosutinib Cmax 1.8-fold and bosutinib AUC 1.7-fold compared to the fasting state.
Croatian: Hrana je povećala Cmax bosutiniba za 1,8 puta, a AUC bosutiniba za 1,7 puta u usporedbi sa stanjem natašte.
English: Bosulif 400 mg film-coated tablets
Croatian: Bosulif 400 mg filmom obložene tablete
English: Uncommon Exfoliative rash, Drug eruption Rare
Croatian: Manje često Eksfolijativni osip, izbijanje kožnih promjena uzrokovano lijekom Rijetko
English: Each film-coated tablet contains 400 mg bosutinib (as monohydrate).
Croatian: Jedna filmom obložena tableta sadrži 400 mg bosutiniba (u obliku hidrata).
English: Bosulif 500 mg film-coated tablets
Croatian: Bosulif 500 mg filmom obložene tablete
English: In patients with severe renal impairment (CLCr < 30 mL/min, estimated by the Cockcroft-Gault formula), the recommended dose of bosutinib is 200 mg daily with food (see sections 4.4 and 5.2).
Croatian: U bolesnika s teškim oštećenjem bubrega (CrCl < 30 ml/min, procijenjen Cockcroft-Gaultovom formulom) preporučena doza bosutiniba je 200 mg na dan s hranom (vidjeti dijelove 4.4 i 5.2).
English: Liver function abnormalities
Croatian: Poremećaji funkcije jetre
English: Each film-coated tablet contains 500 mg bosutinib (as monohydrate).
Croatian: Jedna filmom obložena tableta sadrži 500 mg bosutiniba (u obliku hidrata).
English: - nasopharyngitis.
Croatian: Nehematološke nuspojave
English: Each film-coated tablet contains 100 mg bosutinib (as monohydrate).
Croatian: Jedna filmom obložena tableta sadrži 100 mg bosutiniba (u obliku hidrata).
English: Bosulif 500 mg: each film-coated tablet contains 500 mg bosutinib (as monohydrate).
Croatian: Bosulif 500 mg: jedna filmom obložena tableta sadrži 500 mg bosutiniba (u obliku hidrata).
English: In patients with moderate renal impairment (creatinine clearance [CLCr] 30 to 50 mL/min, estimated by the Cockcroft-Gault formula), the recommended dose of bosutinib is 300 mg daily with food (see sections 4.4 and 5.2).
Croatian: U bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina [CrCl] od 30 do 50 ml/min, procijenjen Cockcroft-Gaultovom formulom) preporučena doza bosutiniba je 300 mg na dan s hranom (vidjeti dijelove 4.4 i 5.2).
English: Bosulif 400 mg film-coated tablets bosutinib
Croatian: Bosulif 400 mg filmom obložene tablete bosutinib
English: Bosulif 500 mg film-coated tablets bosutinib
Croatian: Bosulif 500 mg filmom obložene tablete bosutinib
English: Bosulif 400 mg: each film-coated tablet contains 400 mg bosutinib (as monohydrate).
Croatian: Bosulif 400 mg: jedna filmom obložena tableta sadrži 400 mg bosutiniba (u obliku hidrata).
English: Bosulif 500 mg film-coated tablets Each film-coated tablet contains 500 mg bosutinib (as monohydrate).
Croatian: Bosulif 500 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 500 mg bosutiniba (u obliku hidrata).
English: In patients with severe renal impairment (CLCr < 30 mL/min, calculated by the Cockcroft-Gault formula), the recommended dose of bosutinib is 300 mg daily (see sections 4.4 and 5.2).
Croatian: U bolesnika s teškim oštećenjem bubrega (CrCl <30 ml/min, izračunato Cockroft-Gaultovom formulom), preporučena doza je 300 mg bosutiniba dnevno (vidjeti dijelove 4.4 i 5.2).
English: Bosulif 100 mg film-coated tablets
Croatian: Bosulif 100 mg filmom obložene tablete
English: Ask your doctor for advice before taking Bosulif if you are pregnant or might become pregnant.
Croatian: Ako ste trudni ili biste mogli zatrudnjeti, prije uzimanja lijeka Bosulif zatražite savjet od svoga liječnika.
English: These adverse reactions are presented by system organ class and frequency.
Croatian: Te su nuspojave navedene u skladu s klasifikacijom organskih sustava unutar skupina učestalosti.
English: Bosulif 100 mg: each film-coated tablet contains 100 mg bosutinib (as monohydrate).
Croatian: Bosulif 100 mg: jedna filmom obložena tableta sadrži 100 mg bosutiniba (u obliku hidrata).
English: Bosulif 100 mg film-coated tablets bosutinib
Croatian: Bosulif 100 mg filmom obložene tablete bosutinib
English: Bosulif 400 mg film-coated tablets Each film-coated tablet contains 400 mg bosutinib (as monohydrate).
Croatian: Bosulif 400 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 400 mg bosutiniba (u obliku hidrata).
English: - ritonavir, lopinavir/ritonavir, indinavir, nelfinavir, saquinavir, atazanavir, amprenavir,
Croatian: Osip (uključujući generalizirani osip, makularni osip, makulopapularni osip, papularni osip, pruritični osip)
English: What Bosulif looks like and contents of the pack Bosulif 100 mg film-coated tablets are yellow, oval biconvex, debossed with “Pfizer” on one side and “100” on the other side.
Croatian: Bosulif 100 mg filmom obložene tablete su žute, ovalne, bikonveksne, s utisnutom oznakom "Pfizer" na jednoj strani i "100" na drugoj strani.
English: - itching, urticaria (hives), acne.
Croatian: - svrbež, koprivnjača, akne.
English: Bosulif 100 mg film-coated tablets Each film-coated tablet contains 100 mg bosutinib (as monohydrate).
Croatian: Bosulif 100 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 100 mg bosutiniba (u obliku hidrata).
English: It may harm them, even if their signs of illness are the same as yours.
Croatian: Napomena: Postotci se temelje na broju bolesnika u svakoj od liječenih skupina.